Asset profile

Anlotinib

Small molecule

Phase 3VEGFR1/2/3, FGFR1/2/3, PDGFR-α, c-Kit
Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-09-01.

How the evidence outlook works ↗

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
August 2026 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-08-31 · NCT06634667 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-01 · NCT06043973 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT04136535 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (12)
February 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT06851169 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)
Phase 2HR+/HER2- Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT06874933 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT07139470 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06977828 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-02 · NCT06945705 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-09-15 · NCT07601178 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT07703228 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-11-25 · NCT07330544 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (4)
Phase 2HR-positive, HER2-negative Metastatic Breast Cancer With Brain MetastasesNot yet recruiting
Est. primary completion 2027-12-28 · NCT07745257 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT06141226 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04165330 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (4)
February 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02-15 · NCT07545213 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-24 · NCT04322617 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 2HER2-Negative Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT07396454 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07294261 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
May 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05-15 · NCT07643350 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)
Phase 2Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous TreamtedNot yet recruiting
Est. primary completion 2029-06 · NCT07562581 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
April 2030 (1)
Phase 2HER 2 Negative Breast CancerRecruiting
Est. primary completion 2030-04-30 · NCT07520760 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
April 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-04-10 · NCT06992336 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.

Educational data tool. Grades describe evidence quality, not investment merit.